Gilead Sciences, Inc.’s recent filing unveils that its 10% Owner GILEAD SCIENCES, INC. acquired Company’s shares for reported $0.37 million on Apr 02 ’24. In the deal valued at $0.76 per share,485,250 shares were bought. As a result of this transaction, GILEAD SCIENCES, INC. now holds 7,345,473 shares worth roughly $491.78 million.
Then, Parsey Merdad sold 2,000 shares, generating $145,920 in total proceeds. Upon selling the shares at $72.96, the Chief Medical Officer now owns 96,304 shares.
Before that, Parsey Merdad sold 8,230 shares. Gilead Sciences, Inc. shares valued at $598,624 were divested by the Chief Medical Officer at a price of $72.74 per share. As a result of the transaction, Parsey Merdad now holds 92,706 shares, worth roughly $6.21 million.
Truist downgraded its Gilead Sciences, Inc. [GILD] rating to a Hold from a a Buy in a research note published on February 22, 2024; the price target was decreased to $82 from $91. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in early November with a ‘”a Hold”‘ rating. BofA Securities also remained covering GILD and has increased its forecast on September 08, 2023 with a “Buy” recommendation from previously “Neutral” rating. HSBC Securities started covering the stock on September 06, 2023. It rated GILD as “a Reduce”.
Price Performance Review of GILD
On Monday, Gilead Sciences, Inc. [NASDAQ:GILD] saw its stock jump 0.28% to $66.95. Over the last five days, the stock has lost -1.18%. Gilead Sciences, Inc. shares have fallen nearly -17.36% since the year began. Nevertheless, the stocks have fallen -20.95% over the past one year. While a 52-week high of $87.86 was reached on 01/19/24, a 52-week low of $65.90 was recorded on 04/18/24. SMA at 50 days reached $71.88, while 200 days put it at $76.55. A total of 5.62 million shares were traded, compared to the trading of 10.66 million shares in the previous session.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 66.60, which if violated will result in even more drops to 66.26. On the upside, there is a resistance level at 67.43. A further resistance level may holdings at 67.91. The Relative Strength Index (RSI) on the 14-day chart is 30.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.25%. Stochastics %K at 10.89% indicates the stock is a buying.
The most recent change occurred on July 24, 2023 when Barclays resumed its ‘”an Equal weight”‘ rating for the stock and retained the price target to $80.
